Dr. Druker faced several challenges in developing Imatinib. One of the main obstacles was skepticism from the scientific community and pharmaceutical companies. Many were doubtful that a single drug could effectively target cancer cells without harming normal cells. Additionally, securing funding and conducting clinical trials were significant hurdles. Despite these challenges, Druker's persistence and dedication led to the successful development of Imatinib.
